GELS Gelteq Limited Inc: Company Short-Term Debts

Public company logo of Gelteq Limited (GELS)

Gelteq Limited relies on an innovative gel encapsulation system for nutrient delivery. The evolution of short-term debt load demonstrates liquidity risks, where the 0.00 metric determines this level. The growth of liabilities depends on test outcomes and licenses with tech giants. Its status as a leading developer ensures the company maintains high interest from the global medical sector.

GELS (Gelteq Limited) Company Short-Term Debts history from 10/30/2024 to 10/30/2026

Metric breakdowns and analytics for Gelteq Ltd (GELS)

- stock price and consensus target price:
Stock Price Gelteq Limited Inc|GELS - Consensus Target
- company stock capitalization data:
Market Capitalization Gelteq Limited|GELS - Company Buyout Price
- business book valuation details:
Book Value per Share Gelteq|GELS - Book Capitalization|Market Value to Book Value Ratio gelteq.com|GELS - Aggregate Company Assets
- issuer credit burden and liquidity indicators:
Total Debt to Capital Gelteq Limited|GELS - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Equity Ratio Gelteq Limited Inc|GELS - Company Aggregate Indebtedness|Debts to Book Capitalization Gelteq Limited|GELS - Long-Term Debt|Company Short-Term Debts Gelteq|Quick Liquidity Indicator gelteq.com
- net income and valuation multiples indicators:
GELS - Final Profit
Summary company analysis:gelteq.com (GELS)
Manufactured products of Gelteq Limited

Professional selection of resilient assets begins with an analysis of liquidity and the issuer's ability to service obligations with maturities of up to one year. The dynamics of short-term financial debt measure the operational need for capital, which is critical for Gelteq Limited (GELS) when scaling exclusive B2B developments within its patented gel drug delivery ecosystem.

Main competitors

Vertex - Company Short-Term Debts|Alnylam Pharmaceuticals, Inc. (ALNY) - Company Current Liabilities|INSM: Company Short-Term Debts|UTHR - Short-Term Debt Volume|BMRN (BioMarin Pharmaceutical) - Company Short-Term Debts|Company Short-Term Debts bridgebio.com|Company Short-Term Debt BGM Group Ltd (BGM)|Company Short-Term Debt COGT (Cogent Biosciences Inc)|Company Short-Term Debts XERS (Xeris Biopharma Inc)|Short-Term Debt Volume Keros Corp (KROS)|ARCT: Company Current Liabilities|Current Liabilities ETON|KMDA: Company Short-Term Debts|Short-Term Debt Fulcrum Therapeutics Inc (FULC)|ABEO (Abeona Therapeutics, Inc.) - Company Short-Term Debts|Company Short-Term Indebtedness MREO (Mereo BioPharma Group PLC)|Company Current Liabilities PLX (Protalix BioTherapeutics)|PLRX (pliantrx.com) - Company Short-Term Loans and Borrowings|Company Short-Term Debt Applied Therapeutics APLT|RNTX (Rein Therapeutics Inc.) - Current Liabilities|Aytu Therapeutics - Company Short-Term Debts|Company Short-Term Loans and Borrowings CMMB (Chemomab Therapeutics)|SRXH: Company Short-Term Debts|Polyrizon (PLRZ) - Company Short-Term Debts|Company Short-Term Debt Aeterna Zentaris Inc|CYTH: Company Short-Term Loans and Borrowings|Company Short-Term Debt Inozyme Pharma, Inc. (INZY)|Company Current Liabilities Reneo Pharmaceuticals, Inc RPHM|Company Short-Term Debts CSCI (COSCIENS Biopharma Inc.)